
Ned is a senior editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University. Hoya Saxa.
1826 articles by Ned Pagliarulo
-
FDA authorizes J&J's one-shot coronavirus vaccine
Feb. 27, 2021 -
FDA panel backs J&J's coronavirus vaccine, clearing way for shot's authorization
Feb. 26, 2021 -
Bluebird reveals new details on cancer cases in gene therapy trial
Feb. 26, 2021 -
A play-by-play of the FDA meeting on J&J's one-shot coronavirus vaccine
Feb. 26, 2021 -
Top Moderna executive to leave company later this year
Feb. 25, 2021 -
Former AveXis executives launch gene therapy startup with uncommon targets
Feb. 25, 2021 -
FDA review supports safety, efficacy of J&J coronavirus vaccine
Feb. 24, 2021 -
Beam, capitalizing on stock surge, buys gene therapy tools developer for $120M
Feb. 23, 2021 -
FDA lays out shortened path for testing vaccines against new coronavirus variants
Feb. 22, 2021 -
Why this week's FDA meeting on J&J's coronavirus vaccine will be important
Feb. 22, 2021 -
Pfizer set to double weekly production of coronavirus vaccine
Feb. 19, 2021 -
Bluebird stops studies of sickle cell gene therapy after new cancer cases
Feb. 16, 2021 -
10 biotechs become 1: Centessa launches with $250M to prove unorthodox R&D model
Feb. 16, 2021 -
A gene therapy pipeline takes shape for a cluster of rare diseases
Feb. 12, 2021 -
US secures 200 million more vaccine doses from Pfizer, Moderna
Feb. 12, 2021 -
FDA clears Lilly's COVID-19 antibody cocktail for emergency use
Feb. 10, 2021 -
Editas names new CEO in latest executive shakeup
Feb. 8, 2021 -
Bristol Myers finally wins FDA approval for cancer cell therapy
Feb. 5, 2021 -
Gilead sales propped up by COVID-19 drug Veklury
Feb. 5, 2021 -
J&J asks FDA for emergency clearance of coronavirus vaccine
Feb. 4, 2021 -
Ken Frazier, veteran pharma leader, to step down as Merck CEO
Feb. 4, 2021 -
Jazz Pharma to buy GW Pharma, maker of CBD-based epilepsy drug, for $7.2B
Feb. 3, 2021 -
Pfizer forecasts $15B sales boost from coronavirus vaccine orders
Feb. 2, 2021 -
Bayer agrees to help CureVac produce coronavirus vaccine
Feb. 1, 2021 -
Gilead partners with a cancer biotech, seeking to develop an HIV immunotherapy
Feb. 1, 2021